retatrutide side effects clinical trial results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 VisualAbstract: Retatrutide reduces body weight

Currently available GLP-1 receptor agonists in the UK include: For type 2 diabetes : semaglutide (Ozempic [injection], Rybelsus [oral tablet]), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia) For weight management : semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) Most GLP-1 medications are administered via subcutaneous injection, with dosing frequencies ranging from daily to once weekly depending on the specific formulation

Modalit d'Uso

Vehicle or compounds were administered 60 min prior to the OGTT

Suitable for most skin types.

These medications are generally considered a long term, potentially lifelong treatment, as Yet, 32% of people who begin taking GLP-1 weight loss medications stop within a year due to several reasons, including the high cost and severity of side effects